FULL PAPER
1H), 3.69 (m, 1H), 3.55 (d, J=14.0 Hz, 1H), 3.40–3.06 (m,
Characterization of (S)-N,N-dihexadecyl-
2-((2-hydroxybenzyl)amino)-3-methylbutanamide
(L10)
4H), 1.85 (m, 1H), 1.17 (t, J=6.9 Hz, 3H), 1.12 (t, J=6.9 Hz,
3H), 1.00–0.97 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 172.1,
158.2, 128.9, 128.5, 122.4, 119.1, 116.3, 61.6, 51.2, 41.4, 40.3,
31.6, 20.2, 17.7, 14.6, 13.0. Anal. Calcd for C16H26N2O2: C,
69.03; H, 9.41; N, 10.06. Found: C, 68.78; H, 9.09; N, 9.93.
According the synthetic procedure of L8, L10 (1.35 g, 47% in 4
steps) was obtained from N-Boc-L-valine (928 mg, 4.27 mmol),
dipalmitoylamine (3.69 g, 7.92 mmol, 1.9 equiv.) and salicylal-
dehyde (521 mg, 4.27 mmol, 1.0 equiv.) as a colorless oil after
chromatographic purification (silica gel, hexane/EtOAc=10/1):
Characterization of (S)-N,N-didecyl-
2-((2-hydroxybenzyl)amino)-4-methylpentanamide
(pre-L20)
23
Rf=0.50 (silica gel, hexane/EtOAc=5/1); [α]D À 5.4 (c 1.00
in CHCl3); IR (NaCl) 3280 (OÀ H), 1636 (C=O) cmÀ 1; 1H NMR
(300 MHz, CDCl3) δ 7.16 (dt, J=7.5, 1.2 Hz, 1H), 6.91 (dd,
J=7.5, 1.2 Hz, 1H), 6.84 (d, J=7.5 Hz, 1H), 6.74 (d, J=
7.5 Hz, 1H), 4.05 (d, J=13.8 Hz, 1H), 3.70 (quintet, J=7.5 Hz,
1H), 3.54 (d, J=13.8 Hz, 1H), 3.28–3.17 (m, 2H), 3.11–2.93
(m, 2H), 1.84 (sext, J=6.6 Hz 1H), 1.57–1.26 (s, 56H), 1.01 (d,
J=6.9 Hz, 3H), 1.01 (d, J=6.9 Hz, 3H), 0.88 (t, J=6.6 Hz,
6H); 13C NMR (75 MHz, CDCl3) δ 172.3, 158.1, 128.8, 128.6,
122.4, 119.0, 116.3, 61.6, 51.2, 47.3, 46.0, 31.9, 31.4, 29.7,
29.63, 29.59, 29.52, 29.46, 29.3, 29.1, 27.7, 27.0, 26.8, 22.7,
20.4, 17.3, 14.1. Anal. Calcd for C44H82N2O2: C, 78.74; H,
12.32; N, 4.17. Found: C, 78.37; H, 12.06; N, 4.11.
According the synthetic procedure of L8, pre-L20 (318 mg,
38% in 4 steps) was obtained from N-Boc-L-leucine (391 mg,
1.69 mmol), didecylamine (855 mg, 2.87 mmol, 1.7 equiv.) and
salicylaldehyde (206 mg, 1.69 mmol, 1.0 equiv.) as a colorless
oil after chromatographic purification (silica gel, hexane/
EtOAc=30/1 to 20/1 to 15/1): Rf=0.43 (silica gel, hexane/
23
EtOAc=10/1); [α]D À 26.7 (c 0.99 in CHCl3); IR (NaCl) 3286
1
(OÀ H), 1729 (C=O) cmÀ 1; H NMR (300 MHz, CDCl3) δ 7.16
(dt, J=7.5, 1.2 Hz, 1H), 6.92 (d, J=7.5 Hz, 1H), 6.84 (d, J=
7.5 Hz, 1H), 6.75 (dt, J=7.5, 1.2 Hz, 1H), 4.07 (d, J=13.8 Hz,
1H), 3.61–3.44 (m, 3H), 3.14 (m, 2H), 2.97 (m, 1H), 1.94 (m,
1H), 1.56–1.19 (m, 32H), 0.94–0.85 (m, 12H); 13C NMR
(75 MHz, CDCl3) δ 173.5, 158.3, 128.8, 128.6, 122.4, 119.0,
116.3, 54.6, 51.0, 47.2, 46.3, 42.9, 31.9, 29.6, 29.4, 29.3, 29.3,
29.2, 29.1, 27.7, 27.0, 26.8, 24.6, 23.8, 22.6, 21.0, 14.1. Anal.
Calcd for C33H60N2O2: C, 76.69; H, 11.70; N, 5.42. Found: C,
76.32; H, 11.34; N, 5.48.
Characterization of (S)-N-decyl-
2-((2-hydroxybenzyl)amino)-3-methylbutanamide
(L13)
According the synthetic procedure of L8, L13 (881 mg, 94% in
4
steps) was obtained from N-Boc-L-valine (563 mg,
2.59 mmol), decylamine (1.02 g, 6.48 mmol, 2.5 equiv.) and
salicylaldehyde (316 mg, 2.59 mmol, 1.0 equiv.) as a colorless
oil after chromatographic purification (silica gel, hexane/
Characterization of (S)-N,N-didecyl-
2-((2-hydroxybenzyl)amino)-3-phenylpropanamide
(pre-L21)
24
EtOAc=3/1): Rf=0.60 (silica gel, hexane/EtOAc=1/1); [α]D
À 26.3 (c 1.12 in CHCl3); IR (NaCl) 3311 (OÀ H), 1648 (C=O)
According the synthetic procedure of L8, pre-L21 (193 mg,
22% in 4 steps) was obtained from N-Boc-L-phenylalanine
(424 mg, 1.60 mmol), didecylamine (809 mg, 2.72 mmol,
1.7 equiv.) and salicylaldehyde (195 mg, 1.60 mmol, 1.0 equiv.)
as a colorless oil after chromatographic purification (silica gel,
hexane/EtOAc=30/1 to 20/1 to 15/1): Rf=0.17 (silica gel,
1
cmÀ 1; H NMR (300 MHz, CDCl3) δ 7.18 (m, 1H), 6.94 (m,
1H), 6.85 (dd, J=8.1, 0.9 Hz, 1H), 6.77 (dt, J=7.2, 0.9 Hz,
1H), 5.52 (d, J=5.7 Hz, 1H), 4.10 (d, J=13.8 Hz, 1H), 3.64 (s,
J=13.8 Hz, 1H), 3.33 (q, J=6.0 Hz, 2H), 2.66 (d, J=7.2 Hz,
1H), 1.89 (q, J=3.6 Hz, 1H), 1.52 (q, J=6.9 Hz, 2H), 1.36–
1.23 (m, 14H), 1.01 (d, J=6.9 Hz, 3H), 0.94 (d, J=6.6 Hz,
3H), 0.88 (t, J=6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3)
δ 172.6, 157.6, 128.8, 128.6, 122.4, 119.1, 116.0, 67.2, 50.7,
39.4, 31.8, 31.4, 29.6, 29.49, 29.46, 29.22, 29.19, 26.9, 22.6,
19.6, 18.8, 14.0. Anal. Calcd for C22H38N2O2: C, 72.88; H,
10.56; N, 7.73. Found: C, 72.66; H, 10.95; N, 7.45.
24
hexane/EtOAc=10/1); [α]D À 3.2 (c 1.10 in CHCl3); Rf=0.33
(silica gel, hexane/EtOAc=15/1); IR (NaCl) 3289 (OÀ H), 1637
(C=O) cmÀ 1; 1H NMR (300 MHz, CDCl3) δ 7.29 (m, 1H), 7.25–
7.21 (m, 2H), 7.17–7.12 (m, 3H), 6.89 (dd, J=7.5, 1.5 Hz, 1H),
6.80 (dd, J=8.1, 1.2 Hz, 1H), 6.73 (dt, J=7.5, 1.2 Hz, 1H),
4.02 (d, J=14.1 Hz, 1H), 3.66 (t, J=1.2 Hz, 1H), 3.60 (d, J=
14.1 Hz, 1H), 3.49 (m, 1H), 3.09 (m, 1H), 2.95–2.78 (m, 3H),
2.62 (m, 1H), 1.57–1.28 (m, 32H), 0.91–0.87 (m, 6H); 13C
NMR (75 MHz, CDCl3) δ 172.1, 158.1, 136.8, 129.3, 128.8,
128.6, 128.5, 126.9, 121.9, 119.0, 116.5, 57.7, 50.6, 47.0, 46.6,
40.4, 31.9, 29.6, 29.53, 29.46, 29.37, 29.28, 29.22, 29.1, 29.0,
27.6, 27.1, 26.7, 22.6, 14.1. Anal. Calcd for C36H58N2O2:
C,78.49; H, 10.61; N, 5.09. Found: C, 78.47; H, 10.24; N, 5.37.
Characterization of (S)-N,N-diethyl-
2-((2-hydroxybenzyl)amino)-3-methylbutanamide
(pre-L16)
According the synthetic procedure of L8, pre-L16 (2.03 g 71%
in
4 steps) was obtained from N-Boc-L-valine (2.22 g,
10.2 mmol), dimethylamine (1.87 g, 25.5 mmol, 2.5 equiv.) and
salicylaldehyde (1.25 g, 10.2 mmol, 1.0 equiv.) as a colorless oil
after chromatographic purification (silica gel, hexane/EtOAc=
Characterization of (S)-N,N-didecyl-
2-((2-hydroxybenzyl)amino)-3,3-dimeth-
ylbutanamide (pre-L22)
22
4/1): Rf=0.27 (silica gel, hexane/EtOAc=2/1); [α]D À 3.3 (c
0.78 in CHCl3); IR (NaCl) 3446 (OÀ H), 3294 (NÀ H), 1633
1
(C=O) cmÀ 1; H NMR (300 MHz, CDCl3) δ 7.17 (dt, J=8.1,
According the synthetic procedure of L8, pre-L22 (677 mg,
63% in 4 steps) was obtained from N-Boc-L-tert-leucine
(500 mg, 2.16 mmol), didecylamine (770 mg, 2.59 mmol,
1.5 Hz, 1H), 6.92 (dd, J=8.1, 1.5 Hz, 1H), 6.85 (dd, J=8.1,
0.9 Hz, 1H), 6.75 (dt, J=8.1, 0.9 Hz, 1H), 4.05 (d, J=14.0 Hz,
Adv. Synth. Catal. 2020, 362, 1–23
8
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
��
These are not the final page numbers!